AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01892280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teenwork intervention
Description: Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
Study NCT01892280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: Text message reminders to check blood glucose levels at self-selected times
Study NCT02079779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic-assisted therapy
Description: The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
Study NCT02079779 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical therapy
Description: Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
Study NCT02079779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical therapy
Description: Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
Study NCT04322565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Cochicine 1mg/day
Study NCT01467986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
Study NCT01467986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
Study NCT01519791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
Study NCT01519791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
Study NCT03975829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: dabrafenib oral, twice daily
Study NCT01467986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
Study NCT01467986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed
Study NCT01467986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
Study NCT01467986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed
Study NCT02002286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii Hook F extract (TwHF extract)
Description: The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
Study NCT02002286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cART
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
Study NCT02002286 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cART
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
Study NCT04471129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HFO/O2C/NIV
Description: High-flow oxygen therapy + O2C + Non invasive ventilation
Study NCT04471129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NIV/O2C/HFO
Description: Non invasive ventilation + O2C + High-flow oxygen therapy
Study NCT03020537 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone
Description: Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
Study NCT03975829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: trametinib oral, once daily
Study NCT01814553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Daily treatment starting 40 mg per day
Study NCT01814553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loperamide
Description: Follow cohort assignment and diarrhea management guidelines
Study NCT01864395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Centrifugation Method
Description: Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
Study NCT01864395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online MUF
Description: Hemofilter is used online while the heart-lung machine is connected to the patient.
Study NCT01864395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Offline MUF
Description: Hemofilter is used offline when the heart-lung machine is not connected to the patient.
Study NCT00599963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 1 mg/day
Study NCT00599963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: paricalcitol 1 mg/day
Study NCT04623086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Degludec
Description: Insulin Degludec injection
Study NCT04623086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Insulin Degludec injection
Study NCT04623086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Insulin Glargine injection
Study NCT04623086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
Study NCT03833401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous tissue transplantation
Description: Root canal disinfection and revascularization with patient's own minced pulp tissues
Study NCT03833401 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Root canal revascularization
Description: Root canal disinfection and revascularization without tissue transplantation
Study NCT03747510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CarpX Device
Description: Transverse carpal ligament release with CarpX Device
Study NCT02695537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
Study NCT03239223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
Study NCT04820660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task orientated strengthening training
Description: 1. Standing and reaching in different directions for objects located beyond arm's length to promote loading of the lower limbs and activation of lower limb muscles;~2. Sit-to-stand from various chair heights to strengthen the lower limb extensor muscles;~3. Stepping forward and backward onto blocks of various heights to strengthen the lower limb muscles;~4. Stepping sideways onto blocks of various heights to strengthen the lower limb muscles;~5. forward step-up onto blocks of various heights to strengthen the lower limb muscles;~6. heel(s) raise and lower while maintaining in a standing posture to strengthen the plantar- flexor muscles.~Each workstation was 5 min in duration for each exercise class. Each subject participated in a one-to-one therapy.
Study NCT04820660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training exercises
Description: 1. Stepping forward, backward, and sideways on the exercise step;~2. Stepping over blocks of various heights;~3. Standing up from a chair, walking four steps forward, performing a bilateral stool touch and walking backwards to the chair;~4. Standing up from a chair, walking four steps forward, turning to the right, stepping over the exercise step, turning to the right again and walking forwards to the chair (repeat the exercise circuit in opposite direction);~5. From a sitting position on a 65-cm Swiss ball, performing a range of motion and balance exercises (forward and backward rolling of the~6. Arms; bending the trunk forward and side to side);~7. Performing double-legged stance for 10 s;~8. Performing tandem stance for 10 s;~9. Rising from a chair without the use of the arms;~10. Walking forward and backward with a tandem walking pattern (toes of one foot touching the heel of the foot in front);~11. Performing single- legged stance for 10 s.
Study NCT04207463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.
Study NCT04207463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor
Study NCT04086407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-axis inclinometer attached to the subject's forehead with tape
Description: This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
Study NCT00482586 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
Study NCT00482586 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Patients with hepatic neoplasms who undergo Image-guided Therapy
Study NCT00482586 — intervention group
Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Patients with hepatic neoplasms who undergo Image-guided Therapy
Study NCT03263975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gatorade or Enterade
Description: Commercially available oral rehydration therapies
Study NCT03430765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Single 2-hour individual Acceptance and Commitment Therapy coping skills session.
Study NCT04522115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Group(1) aerobic training: Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.~Group(2) resistance exercise: training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated.
Study NCT00109408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 7.5-20mg po weekly
Study NCT00109408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks
Study NCT01269931 — intervention group
Intervention type: PROCEDURE
Intervention: EBUS-TBNA
Description: Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
Study NCT02897245 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT02227511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fruits
Description: Randomization to extra fruit or nuts as snacks
Study NCT02227511 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nuts
Study NCT02568839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel + trastuzumab sc + pertuzumab
Description: docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
Study NCT02568839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansin
Description: trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
Study NCT04446923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hand antisepsis by scrub
Description: Surgical Hand scrubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
Study NCT04446923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hand antisepsis by scrub
Description: Surgical Hand rubbing using P-1 of both hands using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side.
Study NCT00875797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: parenteral glutamine
Description: Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
Study NCT00875797 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral glutamine
Description: Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
Study NCT01519791 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
Study NCT02882789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371
Description: Cohort1 \& 3: Placebo-controlled, Single ascending dose administration
Study NCT02882789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 400mg
Description: Cohort 2: Crossover designed administration
Study NCT00733291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nelfilcon A contact lens
Description: Commercially marketed, single vision, soft contact lens for daily disposable wear
Study NCT00733291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lens
Description: Commercially marketed, single vision, soft contact lens for daily disposable wear
Study NCT00733291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FID 107027 solution
Description: Commercially marketed solution for contact lens disinfection
Study NCT02352272 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Total Sleep deprivation
Description: Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
Study NCT02352272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Total Sleep deprivation
Description: Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
Study NCT03721601 — intervention group
Intervention type: DEVICE
Intervention: Heart rate monitor chest strap
Description: Simultaneously with 5min Holter recording, 5min recording of chest strap ECG.
Study NCT03721601 — intervention group
Intervention type: DEVICE
Intervention: Wrist band photoplethysmography
Description: Simultaneously with 5min Holter recording, 5min recording wrist band photoplethysmography.
Study NCT01307007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: 15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
Study NCT01307007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Dextran Injection
Description: Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
Study NCT01183156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Re-invitation letter
Description: Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
Study NCT00848289 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interviews
Description: Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
Study NCT01183156 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Invitation to educational meeting
Description: Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
Study NCT02090244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
Study NCT01447602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT-A
Description: Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression